Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
Larimar Therapeutics (LRMR) announced a Type C FDA meeting scheduled for early Q3 2022 to address the ongoing clinical hold on its CTI-1601 program. This meeting aims to resolve issues related to previous mortalities in a non-human primate study, which led to the hold. As of March 31, 2022, Larimar reported $62.6 million in cash, indicating a runway into Q3 2023. The company recorded a net loss of $8.9 million for Q1 2022, an improvement from $12.1 million in Q1 2021, while R&D expenses decreased from $9.0 million to $5.8 million.
- Type C meeting with the FDA scheduled to discuss CTI-1601 clinical hold.
- Cash reserves of $62.6 million, providing runway into Q3 2023.
- Improved net loss from $12.1 million in Q1 2021 to $8.9 million in Q1 2022.
- Reduced research and development expenses from $9.0 million to $5.8 million.
- CTI-1601 remains under clinical hold due to safety concerns.
- Current mortality issues in non-human primate studies unresolved.
- CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022
- Cash at March 31, 2022 of
BALA CYNWYD, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2022 operating and financial results.
“The FDA recently granted our request for a Type C meeting, which is expected to provide an important framework for interactions related to both the hold and our next proposed clinical trial,” said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. “There remains an urgent need for therapies that can slow or prevent the progression of Friedreich’s ataxia, which remains the key motivating factor behind our clinical development efforts. We believe our Phase 1 data demonstrate proof-of-concept for CTI-1601 as a frataxin replacement therapy and its differentiated mechanism of action (MOA). We believe this MOA leaves CTI-1601 uniquely positioned to address the urgent need for disease modifying therapies in Friedreich’s ataxia, as it is designed to address the root cause of this devastating disease. We look forward to its continued development and our upcoming interactions with the FDA.”
CTI-1601 Update
In February 2022, Larimar received feedback from the U.S. Food and Drug Administration (FDA) regarding the May 2021 clinical hold placed on the CTI-1601 program. The May 2021 hold followed the Company’s notification to the agency of mortalities which occurred at the highest dose levels in a 26-week non-human primate (NHP) toxicology study that was designed to support extended dosing of patients with CTI-1601. At the time the hold was placed, Larimar had no interventional clinical trials with patients enrolled or enrolling. In the feedback provided in February 2022, the FDA stated it was maintaining the clinical hold and that additional data are needed to resolve the clinical hold. This feedback followed Larimar’s submission of a complete response to the agency. Larimar subsequently submitted a request for an FDA Type C meeting, which has been granted and has been scheduled for early in the third quarter of 2022. Throughout the course of the interactions associated with the Type C meeting, Larimar intends to work with the FDA to resolve the CTI-1601 clinical hold and agree on the study design and timing of its next proposed clinical trial. The Company plans to provide a regulatory update on CTI-1601 following receipt of the minutes from the scheduled Type C meeting with the FDA.
First Quarter 2022 Financial Results
As of March 31, 2022, the Company had cash and cash equivalents totaling
The Company reported a net loss for the first quarter of 2022 of
Research and development expenses for the first quarter of 2022 were
General and administrative expenses for the first quarter of 2022 and the first quarter of 2021 were both
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s expectations regarding its ability to resolve the clinical hold imposed by the FDA related to CTI-1601, Larimar’s ability to develop and commercialize CTI-1601 and other planned product candidates, Larimar’s planned research and development efforts, including the timing of its CTI-1601 clinical development plan and other matters regarding Larimar’s business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, Larimar’s ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding CTI-1601, the timing and outcome of Larimar’s planned interactions with the FDA concerning the clinical hold on CTI-1601, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including CTI-1601 clinical milestones; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of later clinical trials, and assessments; the ongoing impact of the COVID-19 pandemic on Larimar’s future clinical trials, manufacturing, regulatory and nonclinical study timelines, the ongoing impact of the COVID-19 pandemic and the potential impact of the Russian invasion of Ukraine on Larimar’s ability to raise additional capital and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale CTI-1601’s manufacturing process; Larimar’s ability to obtain regulatory approval for CTI-1601 and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
| Investor Contact: | Company Contact: | |
| Joyce Allaire | Michael Celano | |
| LifeSci Advisors | Chief Financial Officer | |
| jallaire@lifesciadvisors.com | mcelano@larimartx.com | |
| (212) 915-2569 | (484) 414-2715 |
| Larimar Therapeutics, Inc. | ||||||||
| Consolidated Balance Sheet | ||||||||
| (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 62,564 | $ | 70,097 | ||||
| Prepaid expenses and other current assets | 2,315 | 2,107 | ||||||
| Total current assets | 64,879 | 72,204 | ||||||
| Property and equipment, net | 1,067 | 1,049 | ||||||
| Operating lease right-of-use assets | 3,270 | 3,406 | ||||||
| Restricted cash | 1,339 | 1,339 | ||||||
| Other assets | 668 | 669 | ||||||
| Total assets | $ | 71,223 | $ | 78,667 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,417 | $ | 1,660 | ||||
| Accrued expenses | 5,840 | 6,592 | ||||||
| Operating lease liabilities, current | 616 | 594 | ||||||
| Total current liabilities | 8,873 | 8,846 | ||||||
| Operating lease liabilities | 5,245 | 5,408 | ||||||
| Total liabilities | 14,118 | 14,254 | ||||||
| Commitments and contingencies (See Note 9) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock; as of March 31, 2022 and December 31, 2021; no shares issued and outstanding as of March 31, 2022 and December 31, 2021 | — | — | ||||||
| Common stock, authorized as of March 31, 2022 and December 31, 2021; 17,710,450 shares issued and outstanding as of March 31, 2022 and December 31, 2021 | 18 | 18 | ||||||
| Additional paid-in capital | 182,280 | 180,645 | ||||||
| Accumulated deficit | (125,193 | ) | (116,250 | ) | ||||
| Accumulated other comprehensive loss | — | — | ||||||
| Total stockholders’ equity | 57,105 | 64,413 | ||||||
| Total liabilities and stockholders’ equity | $ | 71,223 | $ | 78,667 | ||||
| Larimar Therapeutics, Inc. | ||||||||
| Consolidated Statements of Operations | ||||||||
| (In thousands, except share and per share data) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 5,806 | $ | 8,974 | ||||
| General and administrative | 3,081 | 3,132 | ||||||
| Total operating expenses | 8,887 | 12,106 | ||||||
| Loss from operations | (8,887 | ) | (12,106 | ) | ||||
| Other income, net | (56 | ) | 18 | |||||
| Net loss | $ | (8,943 | ) | $ | (12,088 | ) | ||
| Net loss per share, basic and diluted | $ | (0.49 | ) | $ | (0.76 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 18,338,853 | 15,996,133 | ||||||
FAQ
What is the status of the CTI-1601 program by Larimar Therapeutics?
What were Larimar Therapeutics' financial results for Q1 2022?
How much cash does Larimar Therapeutics have as of March 31, 2022?
What are the key changes in Larimar's research and development expenses for Q1 2022?
